US8038994B2
(en)
|
1996-05-15 |
2011-10-18 |
Quest Pharmatech Inc. |
Combination therapy for treating disease
|
JP4780633B2
(ja)
*
|
1999-06-25 |
2011-09-28 |
イムノゲン インコーポレーティッド |
抗−ErbB抗体−メイタンシノイド複合体を用いた治療方法
|
CN101518653B
(zh)
*
|
1999-06-25 |
2015-08-19 |
基因技术股份有限公司 |
使用抗ErbB抗体-类美坦素偶联物的治疗方法
|
US6825333B1
(en)
|
1999-08-20 |
2004-11-30 |
Chiron Corporation |
EGFH2 genes and gene products
|
KR20110008112A
(ko)
|
1999-08-27 |
2011-01-25 |
제넨테크, 인크. |
항-ErbB2 항체 투여 치료 방법
|
JP4776843B2
(ja)
|
1999-10-01 |
2011-09-21 |
イムノゲン インコーポレーティッド |
免疫複合体及び化学療法剤を用いる癌治療用組成物及び方法
|
SI1282443T1
(sl)
|
2000-05-19 |
2010-01-29 |
Genentech Inc |
Metoda detekcije gena za izboljšanje verjetnosti učinkovitega odziva na terapijo raka z antagonistom ErbB
|
EP1228766A1
(fr)
*
|
2001-01-31 |
2002-08-07 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Phosphorylation de PYK2 par HER3 induit l'invasion de tumeurs
|
AU2002358246B2
(en)
*
|
2001-10-26 |
2008-02-28 |
Oncoquest Pharmaceuticals Inc. |
Combination therapy for treating disease
|
JP2005535297A
(ja)
*
|
2002-04-11 |
2005-11-24 |
アムジェン インコーポレイテッド |
Her−2レセプターチロシンキナーゼ分子およびその使用
|
ITTO20020340A1
(it)
*
|
2002-04-19 |
2003-10-20 |
Biother Di Contardi Gabriella |
Localizzazione del recettore her2 mediante anticorpo umanizzato biotinilato.
|
WO2003101401A2
(fr)
|
2002-06-03 |
2003-12-11 |
Chiron Corporation |
Utilisation de nrg4, ou d'inhibiteurs de nrg4, dans le traitement du cancer du colon et du pancreas
|
AT413486B
(de)
*
|
2002-07-03 |
2006-03-15 |
Igeneon Krebs Immuntherapie |
Verwendung eines antikörpers gerichtet gegen lewis-antigene
|
NO340576B1
(no)
*
|
2002-07-11 |
2017-05-15 |
Hoffmann La Roche |
Rekombinant, humanisert antistoff 2C4 (rhuMab 2C4) for anvendelse sammen med et andre, forskjellig vekstinhiberende anti-ErbB2-antistoff i en fremgangsmåte for behandling av kreft i en pasient og anvendelse derav for fremstilling av et medikament
|
ES2376165T3
(es)
|
2002-07-15 |
2012-03-09 |
F. Hoffmann-La Roche Ag |
Tratamiento del c�?ncer con el anticuerpo dirigido contra erbb2 rhumab 2c4.
|
ATE514717T1
(de)
|
2002-07-18 |
2011-07-15 |
Merus B V |
Rekombinante produktion von antikörpermischungen
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
US7264800B2
(en)
|
2002-07-18 |
2007-09-04 |
Helix Biopharma Corporation |
Method and composition for inhibiting cancer cell growth
|
ES2443416T3
(es)
*
|
2002-07-18 |
2014-02-19 |
Helix Biopharma Corp. |
Uso de ureasa para inhibir el crecimiento de células cancerosas
|
WO2004013180A2
(fr)
|
2002-08-01 |
2004-02-12 |
Immunomedics, Inc. |
Anticorps anti-alpha-fetoproteine immu31, proteines de fusion et procedes d'utilisation de ceux-ci
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
CN101972478B
(zh)
*
|
2002-10-08 |
2012-10-31 |
免疫医疗公司 |
抗体治疗
|
WO2004054622A1
(fr)
*
|
2002-12-13 |
2004-07-01 |
Immunomedics, Inc. |
Immunoconjugues comprenant une liaison intracellulaire clivable
|
EP1613736A4
(fr)
*
|
2003-03-11 |
2007-04-11 |
Dana Farber Cancer Inst Inc |
Inhibition de la pathogenese virale
|
MXPA05011406A
(es)
*
|
2003-04-23 |
2005-12-12 |
Medarex Inc |
Anticuerpos humanizados para el receptor-1 de interferon alfa (ifnar-1).
|
US8088387B2
(en)
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
AT500651B9
(de)
*
|
2003-05-27 |
2010-04-15 |
Altropus Gmbh |
Aktiv immunisierender antikörper
|
EP2395016A3
(fr)
|
2003-05-30 |
2012-12-19 |
Merus B.V. |
Conception et utilisation de régions variables appariées de molécules de liaison spécifiques
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
EP3095793B1
(fr)
|
2003-07-28 |
2020-03-25 |
Genentech, Inc. |
Réduction de protéine a pendant une chromatographie d'affinité sur protéine a
|
EP1658075A4
(fr)
*
|
2003-08-29 |
2008-03-05 |
Cedars Sinai Medical Center |
Composition et methode pour le traitement de cancers et d'autres troubles physiologiques, fondees sur la regulation de la voie ppar-gamma et de l'axe de la her-kinase
|
CN101048425B
(zh)
*
|
2003-09-18 |
2012-12-26 |
雷文生物技术公司 |
Kid3及与其结合的kid3抗体
|
BRPI0416987A
(pt)
*
|
2003-11-28 |
2007-08-21 |
Mitra Medical Technology Ab |
direcionamento de antìgenos de erb
|
MXPA06014065A
(es)
*
|
2004-06-01 |
2007-01-31 |
Genentech Inc |
Conjugados de droga-anticuerpo y metodos.
|
SV2006002143A
(es)
*
|
2004-06-16 |
2006-01-26 |
Genentech Inc |
Uso de un anticuerpo para el tratamiento del cancer resistente al platino
|
ZA200701234B
(en)
|
2004-07-22 |
2008-12-31 |
Genentech Inc |
HER2 antibody composition
|
US20100111856A1
(en)
|
2004-09-23 |
2010-05-06 |
Herman Gill |
Zirconium-radiolabeled, cysteine engineered antibody conjugates
|
JP4948413B2
(ja)
|
2004-09-23 |
2012-06-06 |
ジェネンテック, インコーポレイテッド |
システイン操作抗体および結合体
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
KR20070085855A
(ko)
*
|
2004-12-07 |
2007-08-27 |
제넨테크, 인크. |
Her 억제제를 이용한 치료를 위한 환자 선택 방법
|
CA2592177A1
(fr)
*
|
2005-01-21 |
2006-07-27 |
Genentech, Inc. |
Dosage fixe d'anticorps anti-her
|
BRPI0606542A8
(pt)
|
2005-02-23 |
2018-03-20 |
Genentech Inc |
métodos para aumentar o tempo de progressão de uma doença (ttp)
|
AR053272A1
(es)
*
|
2005-05-11 |
2007-04-25 |
Hoffmann La Roche |
Determinacion de responsivos a la quimioterapia
|
WO2006132788A2
(fr)
|
2005-06-06 |
2006-12-14 |
Genentech, Inc. |
Nouvelles disruptions geniques, nouvelles compositions et nouveaux procedes s'y rapportant
|
US7700299B2
(en)
|
2005-08-12 |
2010-04-20 |
Hoffmann-La Roche Inc. |
Method for predicting the response to a treatment
|
EP1922410A2
(fr)
|
2005-08-15 |
2008-05-21 |
Genentech, Inc. |
Disruptions et compositions géniques et procédés associés
|
KR101164820B1
(ko)
|
2005-09-22 |
2012-07-12 |
삼성전자주식회사 |
디스플레이장치
|
US8080534B2
(en)
|
2005-10-14 |
2011-12-20 |
Phigenix, Inc |
Targeting PAX2 for the treatment of breast cancer
|
EP1962584A2
(fr)
|
2005-11-21 |
2008-09-03 |
Genentech, Inc. |
Nouvelles dissociations de gènes, compositions et procédés les concernant
|
AR056857A1
(es)
|
2005-12-30 |
2007-10-24 |
U3 Pharma Ag |
Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
JP2009527227A
(ja)
|
2006-02-17 |
2009-07-30 |
ジェネンテック・インコーポレーテッド |
遺伝子破壊、それに関連する組成物および方法
|
TW200812615A
(en)
|
2006-03-22 |
2008-03-16 |
Hoffmann La Roche |
Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
|
AR060358A1
(es)
|
2006-04-06 |
2008-06-11 |
Novartis Vaccines & Diagnostic |
Quinazolinas para la inhibicion de pdk 1
|
JP2009536022A
(ja)
|
2006-04-19 |
2009-10-08 |
ジェネンテック・インコーポレーテッド |
新規の遺伝子破壊、それに関連する組成物および方法
|
US8524865B2
(en)
|
2006-05-30 |
2013-09-03 |
Genentech, Inc. |
Antibodies and immunoconjugates and uses therefor
|
MX2008015581A
(es)
*
|
2006-06-05 |
2008-12-17 |
Genentech Inc |
Prolongacion de la supervivencia de pacientes con cancer con niveles elevados de egf o tgf-alfa.
|
PL2056874T3
(pl)
|
2006-08-21 |
2013-02-28 |
Hoffmann La Roche |
Leczenie nowotworu przeciwciałem przeciw VEGF
|
WO2008031531A1
(fr)
*
|
2006-09-15 |
2008-03-20 |
F. Hoffmann-La Roche Ag |
Thérapie antitumorale avec une combinaison d'anticorps anti-her2
|
CN103396486A
(zh)
*
|
2006-10-12 |
2013-11-20 |
中外制药株式会社 |
使用抗ereg抗体的癌症的诊断和治疗
|
KR101541550B1
(ko)
|
2006-10-27 |
2015-08-04 |
제넨테크, 인크. |
항체 및 면역접합체 및 이들의 용도
|
CA2677108A1
(fr)
*
|
2007-03-02 |
2008-09-12 |
Genentech, Inc. |
Element de prevision de la reponse a un inhibiteur de her
|
US9551033B2
(en)
|
2007-06-08 |
2017-01-24 |
Genentech, Inc. |
Gene expression markers of tumor resistance to HER2 inhibitor treatment
|
CA3006428A1
(fr)
|
2007-06-08 |
2008-12-18 |
Genentech, Inc. |
Marqueurs d'expression de gene de resistance tumorale a un traiteme r inhibiteur her2
|
CN101918844A
(zh)
*
|
2007-06-18 |
2010-12-15 |
米迪缪尼有限公司 |
表达epha2和erbb2的细胞的协同治疗
|
ES2528922T3
(es)
|
2007-07-16 |
2015-02-13 |
Genentech, Inc. |
Anticuerpos anti-CD79b humanizados e inmunoconjugados y métodos de uso
|
KR101486615B1
(ko)
|
2007-07-16 |
2015-01-28 |
제넨테크, 인크. |
항-cd79b 항체 및 면역접합체 및 사용 방법
|
KR20140015166A
(ko)
|
2007-10-30 |
2014-02-06 |
제넨테크, 인크. |
양이온 교환 크로마토그래피에 의한 항체 정제
|
EP2215123A1
(fr)
*
|
2007-11-27 |
2010-08-11 |
Ablynx N.V. |
Constructions d'immunoglobuline
|
UY31545A1
(es)
|
2007-12-20 |
2009-08-03 |
|
Nuevos derivados de 2-carboxamida cianoaminourea, sus sales y profarmacos farmacéuticamente aceptables, procesos de preparacion y aplicaciones
|
PE20091174A1
(es)
*
|
2007-12-27 |
2009-08-03 |
Chugai Pharmaceutical Co Ltd |
Formulacion liquida con contenido de alta concentracion de anticuerpo
|
US8454960B2
(en)
|
2008-01-03 |
2013-06-04 |
The Scripps Research Institute |
Multispecific antibody targeting and multivalency through modular recognition domains
|
US8574577B2
(en)
|
2008-01-03 |
2013-11-05 |
The Scripps Research Institute |
VEGF antibodies comprising modular recognition domains
|
US8557242B2
(en)
|
2008-01-03 |
2013-10-15 |
The Scripps Research Institute |
ERBB2 antibodies comprising modular recognition domains
|
US8557243B2
(en)
|
2008-01-03 |
2013-10-15 |
The Scripps Research Institute |
EFGR antibodies comprising modular recognition domains
|
NZ586701A
(en)
|
2008-01-03 |
2013-07-26 |
Scripps Research Inst |
Antibody targeting through a modular recognition domain (MRD) wherein the MRD targets angiopoietin-2 (ANG-2)
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
TWI607019B
(zh)
|
2008-01-31 |
2017-12-01 |
建南德克公司 |
抗-cd79b抗體及免疫共軛物及使用方法
|
KR101881168B1
(ko)
*
|
2008-03-14 |
2018-07-24 |
제넨테크, 인크. |
약물 저항성과 관련된 유전적 변이
|
CA2990929C
(fr)
*
|
2008-03-18 |
2022-04-12 |
Genentech, Inc. |
Combinaisons de conjugues anticorps anti-her2-medicament et d'agents chimiotherapiques, et procedes d'utilisation
|
ES2616728T3
(es)
|
2008-05-23 |
2017-06-14 |
Siwa Corporation |
Procedimientos y composiciones para facilitar la regeneración
|
BRPI0812682A2
(pt)
|
2008-06-16 |
2010-06-22 |
Genentech Inc |
tratamento de cáncer de mama metastático
|
MX2011002372A
(es)
|
2008-09-10 |
2011-04-04 |
Genentech Inc |
Composiciones y metodos para la prevencion de la degradacion oxidativa de proteinas.
|
PL2396036T3
(pl)
|
2009-02-13 |
2017-12-29 |
Immunomedics, Inc. |
Immunokoniugaty z połączeniem rozszczepialnym wewnątrzkomórkowo
|
US20120121596A1
(en)
|
2009-03-20 |
2012-05-17 |
Germaine Fuh |
Bispecific anti-her antibodies
|
BRPI1012676A2
(pt)
|
2009-04-01 |
2016-04-05 |
Genentech Inc |
anticorpos anti-fcrh5 e imunoconjugados e métodos de uso
|
WO2010115553A1
(fr)
|
2009-04-07 |
2010-10-14 |
Roche Glycart Ag |
Anticorps anti-erbb-2/anti-c-met bispécifiques
|
WO2010136569A1
(fr)
|
2009-05-29 |
2010-12-02 |
F. Hoffmann-La Roche Ag |
Modulateurs de la signalisation her2 chez des patients exprimant her2 souffrant d'un cancer de l'estomac
|
US20120141501A1
(en)
|
2009-05-29 |
2012-06-07 |
Forerunner Pharma Research Co. Ltd |
Pharmaceutical Composition Containing Antagonist of EGF Family Ligand as Component
|
US8293753B2
(en)
|
2009-07-02 |
2012-10-23 |
Novartis Ag |
Substituted 2-carboxamide cycloamino ureas
|
US9345661B2
(en)
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
KR101822205B1
(ko)
|
2009-08-11 |
2018-01-25 |
제넨테크, 인크. |
글루타민-비함유 세포 배양 배지에서의 단백질의 생성
|
CN102573909A
(zh)
*
|
2009-08-15 |
2012-07-11 |
霍夫曼-拉罗奇有限公司 |
抗血管发生疗法用于治疗先前治疗过的乳腺癌
|
ES2787234T3
(es)
|
2009-09-01 |
2020-10-15 |
Hoffmann La Roche |
Purificación de proteínas potenciada a través de una elución de proteína A modificada
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
DK2486141T3
(en)
|
2009-10-07 |
2018-04-23 |
Macrogenics Inc |
FC-REGION-CONTAINING POLYPEPTIDES THAT PROVIDE IMPROVED EFFECTOR FUNCTION BASED ON CHANGES OF THE SCOPE OF FUCOSYLATION AND PROCEDURES FOR THEIR USE
|
EP2493929B1
(fr)
*
|
2009-10-28 |
2017-08-16 |
AbbVie Biotherapeutics Inc. |
Anticorps anti-egfr et leurs utilisations
|
SI2496601T1
(sl)
|
2009-11-05 |
2017-09-29 |
F. Hoffmann-La Roche Ag |
Tehnike in sestavek za sekrecijo heterolognih polipeptidov
|
RS60390B1
(sr)
|
2009-11-13 |
2020-07-31 |
Daiichi Sankyo Europe Gmbh |
Materijal i postupci za lečenje ili prevenciju bolesti povezanih sa her-3
|
MX2012006406A
(es)
|
2009-12-04 |
2012-07-25 |
Genentech Inc |
Anticuerpos multiespecificos, analogos de anticuerpo, composiciones y metodos.
|
CA2788715C
(fr)
*
|
2010-02-04 |
2021-06-08 |
Toray Industries, Inc. |
Composition pharmaceutique pour le traitement et/ou la prevention du cancer
|
MY160556A
(en)
*
|
2010-02-18 |
2017-03-15 |
Genentech Inc |
Neuregulin antagonists and use thereof in treating cancer
|
US8609095B2
(en)
|
2010-03-04 |
2013-12-17 |
Symphogen A/S |
Anti-HER2 antibodies and compositions
|
MX354867B
(es)
|
2010-03-22 |
2018-03-23 |
Genentech Inc Star |
Composiciones y métodos útiles para estabilizar formulaciones que contienen proteína.
|
JP2013525484A
(ja)
|
2010-05-03 |
2013-06-20 |
ジェネンテック, インコーポレイテッド |
タンパク質含有製剤の粘度を低減させるために有用な組成物及び方法
|
WO2011146568A1
(fr)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Prédiction de réponses à un inhibiteur de her
|
IL299365A
(en)
|
2010-05-27 |
2023-02-01 |
Genmab As |
Monoclonal antibodies against 2HER
|
NZ604007A
(en)
|
2010-05-27 |
2015-03-27 |
Genmab As |
Monoclonal antibodies against her2 epitope
|
KR20190067277A
(ko)
|
2010-05-28 |
2019-06-14 |
제넨테크, 인크. |
락테이트 데히드로게나제 및 피루베이트 데히드로게나제 키나제의 발현의 하향조절에 의한 락테이트 수준의 감소 및 폴리펩티드 생산의 증가
|
RU2613886C2
(ru)
|
2010-06-03 |
2017-03-21 |
Дженентек, Инк. |
Антитела и иммуноконъюгаты, визуализируемые при помощи иммуно-позитрон-эмиссионной томографии, и способы их применения
|
RU2626537C2
(ru)
|
2010-06-08 |
2017-07-28 |
Дженентек, Инк. |
Полученные с помощью генной инженерии антитела с цистеиновыми заменами и их конъюгаты
|
CA2802756C
(fr)
|
2010-06-24 |
2021-05-04 |
Genentech, Inc. |
Compositions et methodes pour stabiliser des preparations contenant des proteines
|
US20120100166A1
(en)
|
2010-07-15 |
2012-04-26 |
Zyngenia, Inc. |
Ang-2 Binding Complexes and Uses Thereof
|
AR082418A1
(es)
|
2010-08-02 |
2012-12-05 |
Novartis Ag |
Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
|
TW201302793A
(zh)
|
2010-09-03 |
2013-01-16 |
Glaxo Group Ltd |
新穎之抗原結合蛋白
|
US8721571B2
(en)
|
2010-11-22 |
2014-05-13 |
Siwa Corporation |
Selective removal of cells having accumulated agents
|
EP2643353A1
(fr)
|
2010-11-24 |
2013-10-02 |
Novartis AG |
Molécules multi-spécifiques
|
JP5838221B2
(ja)
|
2010-12-21 |
2016-01-06 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
アイソフォーム濃縮抗体調製物及びこれを得る方法
|
WO2012085113A1
(fr)
|
2010-12-23 |
2012-06-28 |
Roche Diagnostics Gmbh |
Agent de liaison
|
SG191153A1
(en)
|
2010-12-23 |
2013-07-31 |
Hoffmann La Roche |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
AU2012213080B2
(en)
|
2011-01-31 |
2014-03-27 |
Novartis Ag |
Novel heterocyclic derivatives
|
CN103649326B
(zh)
*
|
2011-03-08 |
2016-08-17 |
宾夕法尼亚大学理事会 |
用于治疗和诊断用途的抗体样蛋白
|
US20140170149A1
(en)
|
2011-04-20 |
2014-06-19 |
Genmab A/S |
Bispecific antibodies against her2 and cd3
|
CN103857699B
(zh)
|
2011-05-24 |
2016-08-31 |
泽恩格尼亚股份有限公司 |
多价和单价多特异性复合物及其用途
|
BR112014003431A2
(pt)
|
2011-08-17 |
2017-06-13 |
Genentech Inc |
anticorpo, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, agente farmacêutico, uso do anticorpo, método de tratamento de um indivíduo que tem câncer e método de aumento de tempo para recorrência de tumor
|
KR102099991B1
(ko)
|
2011-10-14 |
2020-04-14 |
제넨테크, 인크. |
Her2 이량체화 억제제인 페르투주맙의 용도 및 이를 포함하는 제조품
|
WO2013063229A1
(fr)
|
2011-10-25 |
2013-05-02 |
The Regents Of The University Of Michigan |
Traitement par un agent de ciblage de her2 dans des cancers non amplifiés par her2 ayant des cellules souches cancéreuses exprimant her2
|
KR20140090218A
(ko)
|
2011-10-28 |
2014-07-16 |
노파르티스 아게 |
신규 퓨린 유도체 및 질환의 치료에서의 그의 용도
|
EP2797957B1
(fr)
|
2011-11-23 |
2019-06-19 |
MedImmune, LLC |
Molécules de liaison propres à her3 et utilisation de celles-ci
|
CN104271761B
(zh)
|
2011-11-30 |
2017-03-15 |
霍夫曼-拉罗奇有限公司 |
癌症中的erbb3突变
|
EP2788500A1
(fr)
|
2011-12-09 |
2014-10-15 |
F.Hoffmann-La Roche Ag |
Identification de non-répondeurs aux inhibiteurs de her2
|
AU2012355356B2
(en)
|
2011-12-22 |
2017-10-12 |
Genentech, Inc. |
Ion exchange membrane chromatography
|
TWI593705B
(zh)
|
2011-12-28 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
|
EP3045543A3
(fr)
|
2012-01-31 |
2016-10-12 |
Novartis AG |
Procédé de traitement du cancer
|
EP2638916A1
(fr)
|
2012-03-16 |
2013-09-18 |
Covagen AG |
Nouvelles molécules de liaison ayant une activité antitumorale
|
JP2015514710A
(ja)
|
2012-03-27 |
2015-05-21 |
ジェネンテック, インコーポレイテッド |
Her3阻害剤に関する診断及び治療
|
US9248181B2
(en)
|
2012-04-20 |
2016-02-02 |
Merus B.V. |
Methods and means for the production of Ig-like molecules
|
KR101505157B1
(ko)
*
|
2012-05-08 |
2015-03-24 |
주식회사 종근당 |
항―ErbB2 항체 변이체
|
NZ700924A
(en)
|
2012-05-16 |
2016-02-26 |
Novartis Ag |
Dosage regimen for a pi-3 kinase inhibitor
|
KR102291355B1
(ko)
|
2012-11-30 |
2021-08-19 |
에프. 호프만-라 로슈 아게 |
Pd-l1 억제제 공동치료를 필요로 하는 환자의 식별방법
|
US20150329524A1
(en)
|
2013-01-10 |
2015-11-19 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Fatty acid synthase inhibitors
|
US9180185B2
(en)
|
2013-01-11 |
2015-11-10 |
Hoffman-La Roche Inc. |
Combination therapy of anti-HER3 antibodies
|
EP3424530A1
(fr)
|
2013-03-15 |
2019-01-09 |
Zyngenia, Inc. |
Complexes multispécifiques monovalents et multivalents et leurs utilisations
|
CN104628846B
(zh)
|
2013-11-06 |
2019-12-06 |
三生国健药业(上海)股份有限公司 |
重组蛋白质的纯化方法
|
CN110240655B
(zh)
|
2013-11-19 |
2023-05-16 |
荣昌生物制药(烟台)股份有限公司 |
抗her2抗体及其缀合物
|
EP3074424A4
(fr)
|
2013-11-27 |
2017-06-14 |
Zymeworks Inc. |
Produits de recombinaison de liaison à l'antigène bispécifiques ciblant her2
|
MX2016007376A
(es)
|
2013-12-06 |
2017-05-11 |
Novartis Ag |
Regimen de dosificacion para un inhibidor selectivo alfa-isomorfo de fosfatidilinositol 3-quinasa.
|
BR112016013482B1
(pt)
|
2014-01-31 |
2022-04-19 |
Daiichi Sankyo Company, Limited |
Conjugado de anticorpo anti-her2-fármaco, fármacos antitumor e/ou anticâncer e composição farmacêutica
|
EP3111222A1
(fr)
|
2014-02-26 |
2017-01-04 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
Méthodes de traitement de patients atteints de cancer réagissant à l'inhibiteur d'ezh2 gsk126
|
JP6644717B2
(ja)
|
2014-03-14 |
2020-02-12 |
ジェネンテック, インコーポレイテッド |
異種ポリペプチドを分泌させるための方法及び組成物
|
JP2017512765A
(ja)
|
2014-04-11 |
2017-05-25 |
メディミューン,エルエルシー |
二重特異性her2抗体
|
KR20170052600A
(ko)
|
2014-09-12 |
2017-05-12 |
제넨테크, 인크. |
시스테인 가공된 항체 및 콘주게이트
|
US10385380B2
(en)
|
2014-10-02 |
2019-08-20 |
The Regents Of The University Of California |
Personalized protease assay to measure protease activity in neoplasms
|
US9993535B2
(en)
|
2014-12-18 |
2018-06-12 |
Siwa Corporation |
Method and composition for treating sarcopenia
|
US10358502B2
(en)
|
2014-12-18 |
2019-07-23 |
Siwa Corporation |
Product and method for treating sarcopenia
|
MA41414A
(fr)
|
2015-01-28 |
2017-12-05 |
Centre Nat Rech Scient |
Protéines de liaison agonistes d' icos
|
KR101515535B1
(ko)
|
2015-01-28 |
2015-05-06 |
주식회사 종근당 |
항―ErbB2 항체 변이체
|
US11028182B2
(en)
|
2015-05-13 |
2021-06-08 |
Zymeworks Inc. |
Antigen-binding constructs targeting HER2
|
WO2017025871A1
(fr)
|
2015-08-07 |
2017-02-16 |
Glaxosmithkline Intellectual Property Development Limited |
Polythérapie comprenant des anticorps anti-ctla-4
|
KR20180056689A
(ko)
*
|
2015-10-13 |
2018-05-29 |
시와 코퍼레이션 |
항-age 항체 및 이의 사용 방법
|
AU2016347881A1
(en)
|
2015-11-02 |
2018-05-10 |
Novartis Ag |
Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
|
CN106729743B
(zh)
|
2015-11-23 |
2021-09-21 |
四川科伦博泰生物医药股份有限公司 |
抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
|
CN108884161A
(zh)
|
2015-12-01 |
2018-11-23 |
葛兰素史密斯克莱知识产权发展有限公司 |
联合治疗及其用途和方法
|
AU2016370376B2
(en)
|
2015-12-14 |
2023-12-14 |
Macrogenics, Inc. |
Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
|
CN105646704B
(zh)
*
|
2015-12-28 |
2019-11-15 |
广西医科大学 |
抗p185erbB2人鼠嵌合抗体ChAb26、乳腺特异性表达载体、转基因FVB小鼠及其制备方法
|
CA3021150C
(fr)
|
2016-02-19 |
2023-02-07 |
Siwa Corporation |
Procede et composition pour traiter le cancer, detruire les cellules cancereuses metastatiques et prevenir la metastase cancereuse en utilisant des anticorps contre les produits t erminaux de glycation avancee (age)
|
KR20180119570A
(ko)
*
|
2016-03-15 |
2018-11-02 |
메리맥 파마슈티컬즈, 인크. |
항-ErbB3 항체를 포함하는 병용 요법을 이용한 ER+, HER2-, HRG+ 유방암의 치료
|
KR20180133452A
(ko)
|
2016-04-15 |
2018-12-14 |
시와 코퍼레이션 |
신경퇴행성 질환을 치료하기 위한 항-노화 항체
|
WO2017194554A1
(fr)
|
2016-05-10 |
2017-11-16 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Polythérapies pour le traitement du cancer
|
WO2017196263A1
(fr)
*
|
2016-05-12 |
2017-11-16 |
Agency For Science, Technology And Research |
Anticorps anti-erbb2 et utilisations correspondantes
|
US11213585B2
(en)
|
2016-06-23 |
2022-01-04 |
Siwa Corporation |
Vaccines for use in treating various diseases and disorders
|
WO2018060833A1
(fr)
|
2016-09-27 |
2018-04-05 |
Novartis Ag |
Schéma posologique pour l'alpelisib, un inhibiteur de la phosphatidylinositol 3-kinase spécifique de l'isoforme alpha
|
US20190330368A1
(en)
|
2016-10-07 |
2019-10-31 |
Daiichi Sankyo Company, Limited |
Therapy for drug-resistant cancer by administration of anti-her2 antibody/drug conjugate
|
EP3552626A4
(fr)
|
2016-12-12 |
2020-06-10 |
Daiichi Sankyo Company, Limited |
Association d'un conjugué anticorps-médicament et d'un inhibiteur de point de contrôle immunitaire
|
US10858449B1
(en)
|
2017-01-06 |
2020-12-08 |
Siwa Corporation |
Methods and compositions for treating osteoarthritis
|
US10995151B1
(en)
|
2017-01-06 |
2021-05-04 |
Siwa Corporation |
Methods and compositions for treating disease-related cachexia
|
US10961321B1
(en)
|
2017-01-06 |
2021-03-30 |
Siwa Corporation |
Methods and compositions for treating pain associated with inflammation
|
EP3565845A4
(fr)
*
|
2017-01-06 |
2020-10-07 |
Biosion, Inc. |
Anticorps erbb2 et leurs utilisations
|
US10925937B1
(en)
|
2017-01-06 |
2021-02-23 |
Siwa Corporation |
Vaccines for use in treating juvenile disorders associated with inflammation
|
EP3585431A4
(fr)
|
2017-02-24 |
2020-12-16 |
MacroGenics, Inc. |
Molécules de liaison bispécifiques capables de se lier à cd137 et à des antigènes tumoraux, et leurs utilisations
|
WO2018160138A1
(fr)
|
2017-03-02 |
2018-09-07 |
Aslan Pharmaceuticals Pte Ltd |
Inhibiteur de dhodh pour le traitement du cancer hématologique
|
EP3589661B1
(fr)
|
2017-03-02 |
2023-11-01 |
Genentech, Inc. |
Traitement par adjuvants du cancer du sein her2 positif
|
AR111249A1
(es)
|
2017-03-22 |
2019-06-19 |
Genentech Inc |
Composiciones de anticuerpo optimizadas para el tratamiento de trastornos oculares
|
EP3609923A1
(fr)
|
2017-04-13 |
2020-02-19 |
Siwa Corporation |
Anticorps monoclonal humanisé de produit final de glycation avancée
|
WO2018222135A1
(fr)
|
2017-06-02 |
2018-12-06 |
Aslan Pharmaceuticals Pte Ltd |
Cancérothérapie
|
CN107417791B
(zh)
*
|
2017-08-17 |
2020-09-22 |
合肥瀚科迈博生物技术有限公司 |
抗人ErbB2双特异性抗体、其制备方法及用途
|
CN110944667A
(zh)
|
2017-08-23 |
2020-03-31 |
第一三共株式会社 |
抗体-药物缀合物制剂及其冻干
|
BR112020003466B1
(pt)
|
2017-08-31 |
2023-12-12 |
Daiichi Sankyo Company, Limited |
Métodos de produção de composto, e, composto
|
WO2019044947A1
(fr)
|
2017-08-31 |
2019-03-07 |
第一三共株式会社 |
Procédé amélioré de production d'un conjugué anticorps-médicament
|
CN107789631B
(zh)
*
|
2017-11-03 |
2021-03-16 |
合肥瀚科迈博生物技术有限公司 |
抗人ErbB2双表位抗体-药物偶联物及其应用
|
CA3085432A1
(fr)
|
2017-12-12 |
2019-06-20 |
Macrogenics Inc. |
Derives de molecules de liaison a cd-16 bispecifiques et leur utilisation dans le traitement de maladies
|
US11518801B1
(en)
|
2017-12-22 |
2022-12-06 |
Siwa Corporation |
Methods and compositions for treating diabetes and diabetic complications
|
US11685781B2
(en)
|
2018-02-15 |
2023-06-27 |
Macrogenics, Inc. |
Variant CD3-binding domains and their use in combination therapies for the treatment of disease
|
EP3560945A1
(fr)
|
2018-04-27 |
2019-10-30 |
F. Hoffmann-La Roche AG |
Procédés de purification de polypeptides utilisant des polysorbates
|
AU2019278628A1
(en)
|
2018-05-28 |
2021-01-07 |
Daiichi Sankyo Company, Limited |
Treatment of HER2-mutated cancer by administering anti-HER2 antibody-drug conjugate
|
CA3106995A1
(fr)
|
2018-07-23 |
2020-01-30 |
Trevi Therapeutics, Inc. |
Traitement de la toux chronique, de l'essoufflement ou de la dyspnee a l'aide de compositions de nalbuphine
|
US20210283269A1
(en)
|
2018-07-25 |
2021-09-16 |
Daiichi Sankyo Company, Limited |
Effective method for manufacturing antibody-drug conjugate
|
AU2019311596A1
(en)
|
2018-07-27 |
2021-01-28 |
Daiichi Sankyo Company, Limited |
Protein recognizing drug moiety of antibody-drug conjugate
|
CA3108044A1
(fr)
|
2018-07-31 |
2020-02-06 |
Daiichi Sankyo Company, Limited |
Traitement d'une tumeur cerebrale metastatique par administration d'un conjugue anticorps-medicament
|
EP3834843A4
(fr)
|
2018-08-06 |
2022-05-11 |
Daiichi Sankyo Company, Limited |
Association d'un conjugué anticorps-médicament et d'un inhibiteur de tubuline
|
TW202016317A
(zh)
|
2018-08-23 |
2020-05-01 |
日商第一三共股份有限公司 |
抗體藥物結合物之感受性標記
|
EP3856760A1
(fr)
|
2018-09-25 |
2021-08-04 |
AbSci, LLC |
Procédés de purification de protéines
|
WO2020084503A1
(fr)
|
2018-10-26 |
2020-04-30 |
Cadila Healthcare Limited |
Composition comprenant un anticorps ayant un niveau réduit de variants basiques de celui-ci
|
SG11202106248XA
(en)
|
2018-12-11 |
2021-07-29 |
Daiichi Sankyo Co Ltd |
Combination of antibody-drug conjugate with parp inhibitor
|
SG11202106635WA
(en)
|
2018-12-21 |
2021-07-29 |
Daiichi Sankyo Co Ltd |
Combination of antibody-drug conjugate and kinase inhibitor
|
WO2020160375A1
(fr)
|
2019-02-01 |
2020-08-06 |
Glaxosmithkline Intellectual Property Development Limited |
Polythérapies contre le cancer faisant intervenir de la belantamab mafodotine et un anticorps anti-ox40, utilisations et méthodes associées
|
TW202102266A
(zh)
|
2019-04-01 |
2021-01-16 |
美商建南德克公司 |
用於穩定含有蛋白質之配方之組合物及方法
|
CN112007169B
(zh)
*
|
2019-05-30 |
2022-03-08 |
湖南大学 |
一种核酸适配体药物偶联物及其制备方法和用途
|
CN110205302B
(zh)
*
|
2019-06-24 |
2021-03-23 |
扬州大学 |
一株分泌抗麦考酚酸单克隆抗体的细胞株、其单克隆抗体及其应用
|
EP3990494A1
(fr)
|
2019-06-26 |
2022-05-04 |
GlaxoSmithKline Intellectual Property Development Limited |
Protéines de liaison à l'il1rap
|
CN110551214A
(zh)
*
|
2019-08-27 |
2019-12-10 |
杨澜 |
一种人源化抗Periostin单克隆抗体、及其制备方法和应用
|
JP2023512023A
(ja)
|
2020-01-28 |
2023-03-23 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
併用療法及びその使用及び方法
|
WO2021260582A1
(fr)
|
2020-06-24 |
2021-12-30 |
Astrazeneca Uk Limited |
Association d'un conjugué anticorps-médicament et d'un inhibiteur d'aurora b
|
KR20230043109A
(ko)
|
2020-06-24 |
2023-03-30 |
아스트라제네카 유케이 리미티드 |
항체-약물 접합체 및 atr 억제제의 조합
|
WO2021260583A1
(fr)
|
2020-06-24 |
2021-12-30 |
Astrazeneca Uk Limited |
Association d'un conjugué anticorps-médicament et d'un inhibiteur de la dna-pk
|
EP4171651A1
(fr)
|
2020-06-24 |
2023-05-03 |
AstraZeneca UK Limited |
Combinaison d'un conjugué anticorps-médicament et d'un inhibiteur de l'atm
|
WO2021260578A1
(fr)
|
2020-06-24 |
2021-12-30 |
Astrazeneca Uk Limited |
Combinaison d'un conjugué anticorps-médicament et d'un inhibiteur de cdk9
|
JPWO2022019259A1
(fr)
|
2020-07-20 |
2022-01-27 |
|
|
CA3195117A1
(fr)
|
2020-10-09 |
2022-04-14 |
Jerome Thomas Mettetal Ii |
Association d'un anticorps conjugue et d'un inhibiteur selectif de la parp1
|
CN116916919A
(zh)
|
2020-11-11 |
2023-10-20 |
第一三共株式会社 |
抗体-药物缀合物与抗SIRPα抗体的组合
|
WO2023126822A1
(fr)
|
2021-12-28 |
2023-07-06 |
Astrazeneca Uk Limited |
Association d'un conjugué anticorps-médicament et d'un inhibiteur de rasg12c
|
WO2023209591A1
(fr)
|
2022-04-27 |
2023-11-02 |
Daiichi Sankyo Company, Limited |
Combinaison d'un conjugué anticorps-médicament avec un inhibiteur de l'ezh1 et/ou de l'ezh2
|
WO2023218378A1
(fr)
|
2022-05-11 |
2023-11-16 |
Daiichi Sankyo Company, Limited |
Association combinant un anticorps spécifique d'un antigène tumoral et un inhibiteur de cd47
|
WO2024023750A1
(fr)
|
2022-07-28 |
2024-02-01 |
Astrazeneca Uk Limited |
Association d'un conjugué anticorps-médicament et d'un inhibiteur de point de contrôle bispécifique
|
CN117224689B
(zh)
*
|
2023-11-16 |
2024-02-23 |
上海复宏汉霖生物技术股份有限公司 |
联合抗her2抗体和化疗剂治疗胃癌的用途
|